Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K Pract Neurol. 2016 Apr 25. PMID: 27114560. Abstract CommentRecommendBookmarkWatch